AlzPharm: A Light-Weight RDF Warehouse for Integrating Neurodegenerative Data

Kei Cheung, Ph.D. Yale Center for Medical Informatics



Overview

- Data integration allows a better understanding of brain function by integrating different levels of brain data.
- Most of the neuroscience databases are neither integrated nor interoperable
- Diverse but related data are scattered in different Webaccessible resources and are formatted differently
- We present a Semantic Web approach to building a data integration framework, which involves using RDF as a standard data model to facilitate representation and integration of data

Neuroscience Database Gateway



Current Issue

No Links between related databases

BrainPharm Web Portal

Brain Pharmacological Database: Brain Pharmacological database

Home Parkinson's Epilepsy Alzheimer's NeuronDB

	Chemical		
Name:	Donepezil		
Description	Cholinesterase inhibitor		
Synonym	Donepezil hydrochloride Show other		
Full name	2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one hydro		
Chemical formula	C24H30CINO3		
Structure	Download 0 Bytes		
Molecular target	Acetylcholinesterase Show other		
Action site	Cholinergic synaptic cleft		
Neuron affected	. Cholinergic neuron Show other . Cholinoceptive neuron Show other		
Function affected	.Inhibit acetylcholine hydrolysis and enhance cholinergic synaptic transmission		
Clinical usage	Alzheimer Show other		
Reference			

BrainPharm

AlzForum

ALZHEIMER RESEARCH FORUM	NETWORKING FOR A CURE	Search Get Newsletter Google Search Papers Search Index
WHAT'S NEW	Home Contact Us How to Cite Become a Member	<u>Your Profile</u> →Login
PAPERS OF THE WEEK	Home: Papers of the Week	
Current Papers ARF Recommends Milestone Papers	PAPERS OF THE WEEK	
Search All Papers Search Comments	Papers: Search all papers	Alzheimer's Disease: A
NEWS	Keywords: donepezil O all keywords	Century of Scientific and Clinical Research
Research News	Author: Select Author (e.g. Doe, J)	
Drug News Conference News	Comments By: Select Commentator	Order this Journal of
RESEARCH	Journal: Select Journal	landmark book
AD Hypotheses	Pub Date: From Month 🛛 Year 💌	
Current Hypotheses Hypothesis Eactory	To Month 💙 Year 💙	Forum Calendar
Forums	Limited To: Commented ARF Recommends Milestone	To be scheduled.
Virtual Conferences	Sort By: Publication Date 💌	KnowledgeBases
Enabling Technologies	Reset ARF Search	Telemakus
Workshops Research Tools		Biomarkers for
Compendia Antibodies	SEARCH RESULTS: PAPERS=SEARCH ALL PAPERS; ANY KEYWORDS=DONEPEZIL; COMMENTED	Alzheimer's Disease
Mutations Genes	l to 16 of 16 results 🔹 BACK NEXT	Kilowieugeoase
Research Models		Public Library of
Resources	Kotani S, Yamauchi T, Teramoto T, Ogura H. Pharmacological evidence of cholinerwic implement in adult himocannal neurogenesis in rats	Science
Conference Calendar	Neuroscience. 2006 Aug 2; PubMed Abstract	Fast peer-review, free
Library Grants	VOTE/SUBMIT & COMMENT VIEW COMMENTS	revolution in science
DRUG DEVELOPMENT		publishing.
Companies Tutorial Drugs in Clinical Trials	Mon S, Mon E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin Neurosci. 2006 Apr ;60(2):190-5. <u>PubMed Abstract</u>	
DISEASE MANAGEMENT	VOTE/SUBMIT A COMMENT VIEW COMMENTS	PLOS
About Alzheimer's FAQs Diagnosis	Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R. Effect of age on response to rivastigmine or ionepezil in patients with Alzheimer's	PUBLIC LIBRARY of SCIENCE
Clinical Guidelines Tests	disease. Curr Med Res Opin. 2006 Mar ;22(3):483-94. <u>PubMed Abstract</u>	This Month in PLOS:
Brain Banks Treatment	VOTE/SUBMIT A COMMENT VIEW COMMENTS	Smarter about Clinical
Drugs and Therapies	Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP. Symptomatic effect of	Trials
Patient Care	donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model Exchangemacology (Berl) 2005 Jun 1:180(1):177-00 PubMed	
AD Experiences	Abstract	The Jackson
Eldercare Chats Expert Opinion Ask the Expert	VOTE/SUBMIT A COMMENT VIEW COMMENTS	Laboratory

Semantic Web

- Exposes the semantics of Web-accessible data in a standard machine-readable way so that the data can be more easily interpreted and integrated by computer programs (or Web agents)
- Component technologies of Semantic Web:
 - Uniform Resource Identifiers (URI)
 - Ontology (machine readable)
 - Ontological Languages (RDF, RDFS, and OWL)
 - Semantic-Web-aware Tools (e.g., databases)

Oracle RDF Data Model

- Uses the Oracle RDF Data Model to build a Semantic Web data warehouse for integrating datasets extracted from two independently-developed neuroscience databases:
 - BrainPharm (a subdatabase of SenseLab)
 - domain-specific ontology modeling specific molecular details of drugs
 - SWAN (Semantic Web Applications in Neuromedicine)
 - a project to develop an integrated scientific knowledge infrastructure for the Alzheimer Disease (AD) research community enabled by Semantic Web technology. SWAN models domain-independent concepts including experiments, hypotheses, research statements, and publications

AlzPharm



AlzPharm: Collaboration between SenseLab, SWAN, AlzForum, and Oracle

- Publications
 - Y.K. Lam, L. Marenco, T. Clark, Y. Gao, J. Kinoshita, G. Shepherd, P. Miller, E. Wu, G. Wong, N. Liu, et al. Semantic Web Meets e-Neuroscience: An RDF Use Case. <u>Proceedings of International Workshop on</u> <u>Semantic e-Science</u>, ASWC 2006. 2006. Beijing, China: Jilin University Press, pp. 158-170.
- Demo of AlzPharm
 - <u>http://ontoweb.med.yale.edu/AlzPharm</u>

Conclusion

- Semantic Web technology benefits neuroscience data integration
- The Oracle/RDF system extends SQL to support semantic inferencing.

Future Directions

- Establish more linkages between SenseLab/BrainPharm and AlzForum/SWAN
 - Ontological overlap
 - Content overlap
- Interoperation with other BioRDF data sources (e.g., Entrez Gene)
- From RDF to OWL

Acknowledgment

- Hugo Y.K. Lam (CB&B Ph.D. Program)
- Luis Marenco (YCMI)
- Perry Miller (YCMI)
- Nian Liu (YCMI)
- Chiquito Crasto (YCMI)
- Tim Clark (Mass. General Hospital, Harvard University)
- Yong Gao (Partners)
- June Kinoshita (AlzForum)
- Elizabeth Wu (AlzForum)
- Gwen Wong (AlzForum)
- Gordon Shepherd (Yale Neurobiology)
- Tom Morse (Yale Neurobiology)
- Susie Stephens (Oracle)

Welcome to AlzPharm

at the Yale Center for Medical Informatics



Please select a drug name:	Donepezil	*
or enter your own drug name:	Donepezil	
	Submit Query	′

Note: AlzPharm is a demonstration of how to use the semantic web (<u>Oracle/RDF</u>) technology to integrate drug and publication information related to the Alzheimer's Disease. Such information is stored in two separate data sources (<u>SenseLab/BrainPharm</u> and <u>SWAN/AlzForum</u>). This demo is based on the following paper that was accepted for publication in <u>SeS2006</u>:

Semantic Web Meets e-Neuroscience: An RDF Use Case

Authors: Hugo Y.K. Lam, Luis Marenco, Tim Clark, Yong Gao, June Kinoshita, Gordon Shepherd, Perry Miller, Elizabeth Wu, Gwen Wong, Nian Liu, Chiquito Crasto, Thomas Morse, Susie Stephens, and Kei-Hoi Cheung

<u>AlzPharm</u>

Drug Name	Description	Journal	Title	PubMed ID
Donepezil	Cholinesterase inhibitor	Int J Clin Pract vol. 56	Donepezil: tolerability and safety in Alzheimer's disease.	12469988 [<u>PubMed]</u> [AlzForum]
		Am J Geriatr Pharmacother vol.2	Efficacy and tolerability of memantine in the treatment of dementia.	15903287 [PubMed] [AlzForum]
		N Engl J Med vol.352	Vitamin E and donepezil for the treatment of mild cognitive impairment.	15829527 [PubMed] [AlzForum]
		Drugs Aging vol.22	Causes of syncope in patients with Alzheimer's disease treated with donepezil.	16060718 [PubMed] [AlzForum]
		Br J Clin Pharmacol vol.46 Suppl 1	Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses.	9839758 [<u>PubMed]</u> [AlzForum]
		Nucl Med Commun vol.21	Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.	10717900 [PubMed] [AlzForum]
		Jpn J Pharmacol vol. 89	Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.	12083745 [PubMed] [AlzForum]
		Lancet vol. 367	Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.	16581404 [<u>PubMed]</u> [AlzForum]
		Lancet vol. 363	Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.	15220031 [<u>PubMed]</u> [AlzForum]
		Drug Metab Dispos vol.27	Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat.	10570021 [<u>PubMed]</u> [AlzForum]
		Jpn J Pharmacol vol.81	Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats.	10591480 [PubMed] [AlzForum]

Pharmacological agent		
Name:	Donepezil	
Description	Cholinesterase inhibitor	

Other Categories that may reference "Donepezil" <u>Pathological mechanism</u>: *Pharmacological Agent*

Pathological mechanism that have Donepezil as Pharmacological Agent



<u>AlzPharm</u>

Drug Name	Description	Journal	Title	PubMed ID
Donepezil	Cholinesterase inhibitor	Int J Clin Pract vol. 56	Donepezil: tolerability and safety in Alzheimer's disease.	12469988 [PubMed] [AlzForum]
		Am J Geriatr Pharmacother vol.2	Efficacy and tolerability of memantine in the treatment of dementia.	15903287 [PubMed] [AlzForum]
		N Engl J Med vol.352	Vitamin E and donepezil for the treatment of mild cognitive impairment.	15829527 [PubMed] [AlzForgen]
		Drugs Aging vol.22	Causes of syncope in patients with Alzheimer's disease treated with donepezil.	16060718 [<u>PubMed]</u> [AlzForum]
		Br J Clin Pharmacol vol.46 Suppl 1	Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses.	9839758 [PubMed] [AlzForum]
		Nucl Med Commun vol.21	Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.	10717900 [PubMed] [AlzForum]
		Jpn J Pharmacol vol. 89	Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.	12083745 [PubMed] [AlzForum]
		Lancet vol. 367	Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.	16581404 [PubMed] [AlzForum]
		Lancet vol. 363	Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.	15220031 [PubMed] [AlzForum]
		Drug Metab Dispos vol.27	Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat.	10570021 [PubMed] [AlzForum]
		Jpn J Pharmacol vol.81	Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats.	10591480 [PubMed] [AlzForum]
1				

ALZHEIMER RESEARCH FORUM	NETWORKING FOR A CURE
WHAT'S NEW	Home +Contact Us +How to Cite +Become a Member +Your Profile +Logout
PAPERS OF THE WEEK	Home: Papers of the Week
Current Papers ARF Recommends Milestone Papers Search All Papers Search Comments	ANNOTATION ARF RECOMMENDS Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, That Fark Intervention Trial Bears
NEWS	LJ, . Vitamin E and donepezil for the treatment of mild cognitive
Research News Drug News Conference News	impairment. N Engl J Med. 2005 Jun 9 ; 352(23):2379-88. PubMed Abstract, Telemakus Biomarker Paper
RESEARCH	VOTE/SUBMIT A COMMENT Printable version Desperately
AD Hypotheses Current Hypotheses Hypothesis Factory Forums Live Discussions Virtual Conferences Interviews Enabling Technologies Workshops Research Tools Compendia Antibodies Mutations Genes Research Models Patents Resources Jobs Conference Calendar Library Grants	Comments on Paper and Primary News Seeking Primary News: Early Intervention Trial Bears Little Fruit, but Sows Antibodies Collaborators Submitted 15 April 2005 Posted 15 April 2005 Leon Thal and Ron Petersen presented data at the AAN meeting on 4/13/05 that was published today in the NEJM. It compared the effects of donepezil, vitamin E, and placebo in patients who met clinical criteria for amnestic mild cognitive impairment (MCI). The primary endpoint of the study was worsening of clinical outcome so that diagnosis converted to AD. There was no difference among the groups in primary outcome. However, donepezil-treated subjects performed significantly better than the other groups for a year on several cognitive measures. There was little to no appreciable effect of vitamin E. Further, more than half of the subjects were ApoE4-positive in the study. The effects of donepezil were more Appril 2005 Appril 2005 Appril 2005 Appril 2005 Appril 2005 Appril 2005
Companies Tutorial Drugs in Clinical Trials DISEASE MANAGEMENT About Alzheimer's FAQs Diagnosis Clinical Guidelines Tests Brain Banks	 pronounced in this group, and the effects were seen for longer (18-24 months). Why the effect is more pronounced in ApoE4-positive subjects is not clear. One possibility is that a greater percentage of these patients actually have AD neuropathology underlying their cognitive change. It appears that the effects of donepezil are actually very similar in amnestic MCI to those Read more <u>View all comments by David Holtzman</u>

Brain Banks Treatment Drugs and Therapies Caregiving Patient Care Support Directory AD Experiences Eldercare Chats Expert Opinion Ask the Expert

COMMUNITY

Member Directory Researcher Profiles Institutes and Labs

ABOUT THE SITE

Mission ARF Team Advisory Board ARF Awards Donations Partnerships Fan Mail Support Us

RETURN TO TOP

Primary News: Early Intervention Trial Bears Little Fruit, but Sows <u>Hope</u>

Comment by: Deborah Blacker Submitted 15 April 2005

Posted 15 April 2005

The possible effect of this study on the use of cholinesterase inhibitors is a complex issue because the widespread use of donepezil and other cholinesterase inhibitors is for established AD, not MCI, and the study doesn't speak to that. I believe use for AD will continue, although effects there are modest and time-limited, too. The impact of the results on the use of cholinesterase inhibitors for MCI is less clear. First, MCI is not often recognized clinically, and I doubt the term is used very often outside of Alzheimer centers and specialty memory clinics. In those settings, to my limited knowledge, these medications are widely used, and I'm not sure this study would change that, as it does show some limited benefits for donepezil. Given the recent FDA MedWatch for galantamine (based on excess deaths in large MCI trials), I don't think we can assume that all cholinesterase inhibitors will be treated the same. In any case, the big change in practice should be for vitamin E, also widely used, both by those with a diagnosis of MCI and those with memory changes who... Read more

View all comments by Deborah Blacker